Eritrea vs Guatemala: Average cost of multi drug-resistant tuberculosis treatment
Eritrea
793 constant 2022 US$
in 2024
Guatemala
813 constant 2022 US$
in 2024
Eritrea rank
62nd
Guatemala rank
61st
Average cost of multi drug-resistant tuberculosis treatment over time
- Eritrea
- Guatemala
How they compare
Guatemala currently reports 813 constant 2022 US$ against 793 constant 2022 US$ in Eritrea, a difference of 20 constant 2022 US$.
The two have swapped places 1 time across 7 shared years of data; in 2018 it was Eritrea ahead.
Eritrea ranks 62nd and Guatemala ranks 61st of 92 countries.
Eritrea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eritrea | Guatemala | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,666 constant 2022 US$ | 646.5 constant 2022 US$ | 2,019 constant 2022 US$ | Eritrea |
| 2020s | 3,106 constant 2022 US$ | 781.2 constant 2022 US$ | 2,325 constant 2022 US$ | Eritrea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Eritrea or Guatemala?
- Guatemala, at 813 constant 2022 US$ against 793 constant 2022 US$ in Eritrea as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Eritrea and Guatemala?
- 20 constant 2022 US$, with Guatemala ahead.
- How many years of comparable data are there for Eritrea and Guatemala?
- 7 years are reported by both, from 2018 to 2024.
- How do Eritrea and Guatemala rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Eritrea ranks 62nd and Guatemala ranks 61st of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.